Literature DB >> 20511409

Central neuronal activation and pressor responses induced by circulating ANG II: role of the brain aldosterone-"ouabain" pathway.

Bing S Huang1, Sara Ahmadi, Monir Ahmad, Roselyn A White, Frans H H Leenen.   

Abstract

An increase in plasma ANG II causes neuronal activation in hypothalamic nuclei and a slow pressor response, presumably by increasing sympathetic drive. We evaluated whether the activation of a neuromodulatory pathway, involving aldosterone and "ouabain," is involved in these responses. In Wistar rats, the subcutaneous infusion of ANG II at 150 and 500 ng x kg(-1) x min(-1) gradually increased blood pressure up to 60 mmHg at the highest dose. ANG II at 500 ng x kg(-1) x min(-1) increased plasma ANG II by 4-fold, plasma aldosterone by 25-fold, and hypothalamic aldosterone by 3-fold. The intracerebroventricular infusion of an aldosterone synthase (AS) inhibitor prevented the ANG II-induced increase in hypothalamic aldosterone without affecting the increase in plasma aldosterone. Neuronal activity, as assessed by Fra-like immunoreactivity, increased transiently in the subfornical organ (SFO) but progressively in the paraventricular nucleus (PVN) and supraoptic nucleus (SON). The central infusion of the AS inhibitor or a mineralocorticoid receptor blocker markedly attenuated the ANG II-induced neuronal activation in the PVN but not in the SON. Pressor responses to ANG II at 150 ng x kg(-1) x min(-1) were abolished by an intracerebroventricular infusion of the AS inhibitor. Pressor responses to ANG II at 500 ng x kg(-1) x min(-1) were attenuated by the central infusion of the AS inhibitor or the mineralocorticoid receptor blocker by 70-80% and by Digibind (to bind "ouabain") by 50%. These results suggest a novel central nervous system mechanism for the ANG II-induced slow pressor response, i.e., circulating ANG II activates the SFO, leading to the direct activation of the PVN and SON, and, in addition, via aldosterone-dependent amplifying mechanisms, causes sustained activation of the PVN and thereby hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511409     DOI: 10.1152/ajpheart.00256.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  40 in total

Review 1.  Central neuromodulatory pathways regulating sympathetic activity in hypertension.

Authors:  Alexander Gabor; Frans H H Leenen
Journal:  J Appl Physiol (1985)       Date:  2012-07-05

2.  SOD1 overexpression in paraventricular nucleus improves post-infarct myocardial remodeling and ventricular function.

Authors:  Juan Gao; Ming-Kui Zhong; Zhi-Dan Fan; Ning Yuan; Ye-Bo Zhou; Feng Zhang; Xing-Ya Gao; Guo-Qing Zhu
Journal:  Pflugers Arch       Date:  2011-10-18       Impact factor: 3.657

Review 3.  Pivotal role of α2 Na+ pumps and their high affinity ouabain binding site in cardiovascular health and disease.

Authors:  Mordecai P Blaustein; Ling Chen; John M Hamlyn; Frans H H Leenen; Jerry B Lingrel; W Gil Wier; Jin Zhang
Journal:  J Physiol       Date:  2016-07-31       Impact factor: 5.182

Review 4.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 5.  Hypothalamic Signaling in Body Fluid Homeostasis and Hypertension.

Authors:  Brian J Kinsman; Haley N Nation; Sean D Stocker
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

6.  Aldosterone Mediated Regulation of Epithelial Sodium Channel (ENaC) Subunits in the Rat Hypothalamus.

Authors:  Natalie J Mills; Kaustubh Sharma; Masudul Haque; Meagan Moore; Ryoichi Teruyama
Journal:  Neuroscience       Date:  2018-09-06       Impact factor: 3.590

Review 7.  The roles of sensitization and neuroplasticity in the long-term regulation of blood pressure and hypertension.

Authors:  Alan Kim Johnson; Zhongming Zhang; Sarah C Clayton; Terry G Beltz; Seth W Hurley; Robert L Thunhorst; Baojian Xue
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-19       Impact factor: 3.619

8.  Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.

Authors:  Prafull Raheja; Angela Price; Zhongyun Wang; Debbie Arbique; Beverley Adams-Huet; Richard J Auchus; Wanpen Vongpatanasin
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

9.  Comparison of arterial pressure and plasma ANG II responses to three methods of subcutaneous ANG II administration.

Authors:  Marcos T Kuroki; Gregory D Fink; John W Osborn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-03       Impact factor: 4.733

Review 10.  Endogenous Ouabain: Recent Advances and Controversies.

Authors:  John M Hamlyn; Mordecai P Blaustein
Journal:  Hypertension       Date:  2016-07-25       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.